2,761 Shares in Medtronic PLC (NYSE:MDT) Acquired by Hayden Royal LLC

Share on StockTwits

Hayden Royal LLC purchased a new position in shares of Medtronic PLC (NYSE:MDT) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 2,761 shares of the medical technology company’s stock, valued at approximately $275,000.

Several other hedge funds also recently bought and sold shares of MDT. Spectrum Management Group Inc. raised its position in shares of Medtronic by 353.8% in the first quarter. Spectrum Management Group Inc. now owns 413 shares of the medical technology company’s stock valued at $38,000 after purchasing an additional 322 shares during the period. Mackey Komara & Dankovich LLC bought a new position in shares of Medtronic in the first quarter valued at approximately $38,000. Rocky Mountain Advisers LLC raised its position in shares of Medtronic by 100.0% in the second quarter. Rocky Mountain Advisers LLC now owns 400 shares of the medical technology company’s stock valued at $39,000 after purchasing an additional 200 shares during the period. Motco raised its position in shares of Medtronic by 159.3% in the first quarter. Motco now owns 516 shares of the medical technology company’s stock valued at $47,000 after purchasing an additional 317 shares during the period. Finally, Stuart Chaussee & Associates Inc. bought a new position in shares of Medtronic in the first quarter valued at approximately $48,000. Institutional investors and hedge funds own 80.65% of the company’s stock.

In other Medtronic news, EVP Hoedt Rob Ten sold 9,000 shares of Medtronic stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $91.88, for a total transaction of $826,920.00. Following the sale, the executive vice president now owns 58,785 shares in the company, valued at $5,401,165.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Bradley E. Lerman sold 4,000 shares of Medtronic stock in a transaction on Monday, August 5th. The stock was sold at an average price of $100.31, for a total transaction of $401,240.00. Following the sale, the senior vice president now owns 52,906 shares in the company, valued at approximately $5,307,000.86. The disclosure for this sale can be found here. Insiders have sold 95,701 shares of company stock worth $9,318,744 in the last ninety days. 0.28% of the stock is currently owned by insiders.

Shares of MDT stock opened at $102.40 on Wednesday. Medtronic PLC has a 1 year low of $81.66 and a 1 year high of $103.95. The business’s fifty day moving average is $100.33. The company has a market capitalization of $136.96 billion, a price-to-earnings ratio of 19.62, a P/E/G ratio of 2.60 and a beta of 0.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.59 and a quick ratio of 2.15.

Medtronic (NYSE:MDT) last announced its earnings results on Thursday, May 23rd. The medical technology company reported $1.54 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.47 by $0.07. Medtronic had a net margin of 15.15% and a return on equity of 14.16%. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.12 billion. During the same quarter in the previous year, the firm posted $1.42 earnings per share. Medtronic’s revenue was up .0% compared to the same quarter last year. As a group, equities analysts anticipate that Medtronic PLC will post 5.48 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Thursday, July 25th. Investors of record on Monday, July 8th were given a dividend of $0.54 per share. The ex-dividend date of this dividend was Friday, July 5th. This represents a $2.16 dividend on an annualized basis and a yield of 2.11%. This is a positive change from Medtronic’s previous quarterly dividend of $0.50. Medtronic’s payout ratio is 41.38%.

A number of research firms have recently commented on MDT. Northland Securities reissued a “hold” rating and issued a $100.00 price target on shares of Medtronic in a research report on Thursday, June 20th. Cowen reissued an “outperform” rating and issued a $111.00 price target (up previously from $99.00) on shares of Medtronic in a research report on Wednesday. ValuEngine lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Wells Fargo & Co raised shares of Medtronic from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $100.00 to $110.00 in a research report on Tuesday, June 4th. Finally, Zacks Investment Research raised shares of Medtronic from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. Seven investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $106.27.

Medtronic Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Featured Article: What are no-load funds?

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Recent Analysts’ Ratings Changes for Sanmina
Recent Analysts’ Ratings Changes for Sanmina
Recent Research Analysts’ Ratings Changes for Avid Bioservices
Recent Research Analysts’ Ratings Changes for Avid Bioservices
Research Analysts’ Weekly Ratings Updates for American National BankShares
Research Analysts’ Weekly Ratings Updates for American National BankShares
Karpus Management Inc. Has $23.32 Million Holdings in ISHARES TR/CORE DIVID GR ETF
Karpus Management Inc. Has $23.32 Million Holdings in ISHARES TR/CORE DIVID GR ETF
STRATA Skin Sciences  Receives “Buy” Rating from HC Wainwright
STRATA Skin Sciences Receives “Buy” Rating from HC Wainwright
First Internet Bancorp  Announces $0.06 Quarterly Dividend
First Internet Bancorp Announces $0.06 Quarterly Dividend


© 2006-2019 Ticker Report